QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:CYTK

Cytokinetics - CYTK Stock Forecast, Price & News

$43.12
-0.13 (-0.30%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$43.05
$44.03
50-Day Range
$35.77
$47.41
52-Week Range
$29.67
$55.80
Volume
405,915 shs
Average Volume
863,162 shs
Market Capitalization
$4.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.69

Cytokinetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
38.4% Upside
$59.69 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.79mentions of Cytokinetics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.08 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.07) to ($4.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

304th out of 1,055 stocks

Pharmaceutical Preparations Industry

143rd out of 519 stocks


CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Cytokinetics Stock Trading Halted Today
Is Cytokinetics (CYTK) a Good Long-Term Investment?
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
253
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$59.69
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+38.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-215,310,000.00
Net Margins
-190.34%
Pretax Margin
-190.34%

Debt

Sales & Book Value

Annual Sales
$70.43 million
Book Value
$2.91 per share

Miscellaneous

Free Float
89,899,000
Market Cap
$4.08 billion
Optionable
Optionable
Beta
0.96

Social Links


Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 59)
    CEO, Pres & Director
    Comp: $1.08M
  • Mr. Ching W. JawMr. Ching W. Jaw (Age 60)
    Sr. VP & CFO
    Comp: $645.6k
  • Dr. Fady Ibraham Malik FACC (Age 59)
    M.D., Ph.D., Exec. VP of R&D
    Comp: $733.08k
  • Mr. Andrew M. Callos (Age 67)
    Exec. VP & Chief Commercial Officer
    Comp: $411.85k
  • Dr. James A. Spudich Ph.D. (Age 81)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Jeff Lotz
    VP of Sales & Operations
  • Mr. Robert C. Wong (Age 55)
    VP & Chief Accounting Officer
  • Ms. Joanna Siegall
    Associate Director of Corp. Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer
  • Mr. Scott R. Jordan
    Sr. VP of Global Marketing & Commercial Strategy













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2023?

9 analysts have issued 1 year target prices for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they anticipate the company's share price to reach $59.69 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 at the beginning of 2023. Since then, CYTK stock has decreased by 5.6% and is now trading at $43.27.
View the best growth stocks for 2023 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.09. The biopharmaceutical company had revenue of $2.52 million for the quarter, compared to analyst estimates of $2.26 million. Cytokinetics had a negative trailing twelve-month return on equity of 225.84% and a negative net margin of 190.34%.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.30%), Allspring Global Investments Holdings LLC (0.20%), Peregrine Capital Management LLC (0.17%), Moody Aldrich Partners LLC (0.10%), State of Alaska Department of Revenue (0.07%) and Yousif Capital Management LLC (0.07%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $43.27.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $4.09 billion and generates $70.43 million in revenue each year. The biopharmaceutical company earns $-215,310,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 253 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 1/27/2023 by MarketBeat.com Staff